Global Chemotherapy Market to Experience a Market Growth of CAGR 6.2% during the Assessment Period| Top Key Competitors Analysis- GlaxoSmithKline, AstraZeneca, Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb etc.

Chemotherapy, aka chemo, is a treatment procedure that is used to treat cancer by using anti-cancer drugs. The treatment aims to stop or kill the cancer cells as well as the fast-growing cells while causing the least possible damage to the normal cells. Considered as a systematic therapy, chemotherapy prevents the cancer cells from growing, dividing, and multiplying. The anti-cancer drugs travel through the bloodstream and helps to kill the cancer cells present throughout the body. It can also be transmitted in a targeted manner in the affected cancer sites. Chemotherapy is used for the treatment of various forms of cancer, including myeloma, leukemia, ovarian cancer, sarcoma, breast cancer, lung cancer, lymphoma, and others. The intensity of the treatment has various side effects on the human body such as alopecia, fatigue, nausea and vomiting, hair loss, fatigue, mucositis, hearing impairment, loss of appetite, and many others.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5791

The global chemotherapy market is projected to grow at a gradual pace of 6.2% during the forecast period of 2017 to 2023. The market is driven by increasing prevalence of the various cancer types like myeloma, breast cancer, lung cancer, lymphoma, sarcoma, and others. The growing emphasis on R&D coupled with rapid technological advancement in the field of oncology is slated to drive the global market growth of chemotherapy.

On the contrary, high treatment cost and poor reimbursement policies in developing economies are some of the factors that could restrain the growth of the market during the assessment period.

Market Segmentation

The segmentation of the global Chemotherapy market is divided on the basis of indication, drugs, route of drug administration, and end-user.

By Indication, the market is segregated into lymphoma, leukemia, myeloma, breast cancer, sarcoma, lung cancer, and ovarian cancer, and others.

By Route of Drug Administration, the market divides into oral and intravenous.

By end-user, the market includes research institutes, hospitals, and others.

By drugs, it includes antimetabolites, alkylating agents, mitotic inhibitors, anti-tumor antibiotics, topoisomerase inhibitors, and others. The anti-tumor antibiotics are further narrowed down into chromomycin and anthracyclines. The alkylating agents get divided into ethylenimines, mustard gas derivatives, hydrazines and triazines, alkyl sulfonates, and others. The topoisomerase inhibitors is sub-segmented into Topoisomerase I inhibitors and Topoisomerase II inhibitors.

Regional Analysis

The regional segmentation of the global Chemotherapy market includes America, Europe, Asia-Pacific, and Middle East & Africa.

The American chemotherapy market holds close to half of the global market share. It is driven by the increasing pool of market players in manufacturing chemotherapy drugs, the increasing expenditure in healthcare, and the rising patient population. Lifestyle changes and a growing population addicted to smoking and drinking are also key drivers of the market in this region. It is also worth noting that the availability of advanced healthcare facilities and use of modern technologies for cancer research and treatment purposes also has a positive influence on the market growth.

Following America, Europe stands tall as the second-largest market, wherein Germany and France act as the major contributors to the region. The Asia-Pacific region holds the tag for being the fastest-growing region globally. In the Middle East & Africa region, the awareness concerning cancer, its diagnosis, and the available treatment options drive the growth of the market in this region.

Competitive Analysis

The global Chemotherapy market comprises of various key players, including Eli Lilly & Company (U.S.), Teva Pharmaceuticals Industries (Japan), ImClone Systems Inc. (U.S.), GlaxoSmithKline (U.K.), Schering-Plough (U.S.), Pfizer Inc. (U.S.), Novartis (Germany), AstraZeneca (U.K), CELGENE CORPORATION (U.S.), Amgen Inc (U.S.), Chemo Espana SL (Spain), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche Ltd ( Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sanofi (France), and others.

On January 2019, the chemical engineers at the University of California (UC), US, have come up with a 3D printed ‘drug sponge.’ The development can help curb down the side-effects of chemotherapy with its capability of absorbing excess drugs.

On January 2019, researchers at the Gene Editing Institute in Newark, Delaware, made a monumental medical leap by successfully treating chemotherapy-resistant lung cancer cells with the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene-editing technique.

Browse Complete 100 Pages Premium Research Report @ https://www.marketresearchfuture.com/reports/chemotherapy-market-5791

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.